Stem-Cell Transplantation Beneficial for Scleroderma

This article originally appeared here.
Share this content:
Stem-Cell Transplantation Beneficial for Scleroderma
Stem-Cell Transplantation Beneficial for Scleroderma

WEDNESDAY, Jan. 3, 2018 (HealthDay News) -- For patients with scleroderma, myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation is associated with lasting benefits, according to a study published online Jan. 3 in the New England Journal of Medicine.

Keith M. Sullivan, M.D., from the Duke University Medical Center in Durham, N.C., and colleagues randomized adults with severe scleroderma to undergo myeloablative autologous stem-cell transplantation or receive cyclophosphamide (36 and 39 participants, respectively).

The researchers found that at 54 months the global rank composite scores showed the superiority of transplantation (67 and 33 percent of 1,404 pairwise comparisons favored transplantation and cyclophosphamide, respectively; P = 0.01) in the intention-to-treat population. The rate of event-free survival at 54 months was 79 and 50 percent in the transplantation and cyclophosphamide groups, respectively, in the per-protocol population (P = 0.02). Transplantation was also favored in Kaplan-Meier estimates of event-free survival (74 versus 47 percent; P = 0.03) and overall survival (86 versus 51 percent; P = 0.02) at 72 months. By 54 months, 9 and 44 percent of patients in the transplantation and cyclophosphamide groups, respectively, had initiated disease-modifying antirheumatic drugs (P = 0.001). Treatment-related mortality was 3 and 6 percent at 54 and 72 months, respectively, in the transplantation group versus 0 percent in the cyclophosphamide group.

"Myeloablative autologous hematopoietic stem-cell transplantation achieved long-term benefits in patients with scleroderma, including improved event-free and overall survival, at a cost of increased expected toxicity," the authors write.

One author disclosed financial ties to Novartis.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »